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Abstract
Background
The prevalence of chronic kidney disease (CKD) is high in general populations around the
world. Targeted testing and screening for CKD are often conducted to help identify individu-
als that may benefit from treatment to ameliorate or prevent their disease progression.
Aims
This systematic review examines the methods used in economic evaluations of testing and
screening in CKD, with a particular focus on whether test accuracy has been considered,
and how analysis has incorporated issues that may be important to the patient, such as the
impact of testing on quality of life and the costs they incur.
Methods
Articles that described model-based economic evaluations of patient testing interventions
focused on CKD were identified through the searching of electronic databases and the
hand searching of the bibliographies of the included studies.
Results
The initial electronic searches identified 2,671 papers of which 21 were included in the final
review. Eighteen studies focused on proteinuria, three evaluated glomerular filtration rate
testing and one included both tests. The full impact of inaccurate test results was frequently
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not considered in economic evaluations in this setting as a societal perspective was rarely
adopted. The impact of false positive tests on patients in terms of the costs incurred in re-
attending for repeat testing, and the anxiety associated with a positive test was almost
always overlooked. In one study where the impact of a false positive test on patient quality
of life was examined in sensitivity analysis, it had a significant impact on the conclusions
drawn from the model.
Conclusion
Future economic evaluations of kidney function testing should examine testing and monitor-
ing pathways from the perspective of patients, to ensure that issues that are important to
patients, such as the possibility of inaccurate test results, are properly considered in the
analysis.
Introduction
The prevalence of chronic kidney disease (CKD) is high in general populations globally [1–7].
For example, data from the Health Survey in England 2009 and 2010 found the prevalence of
low excretory kidney function (glomerular filtration rate [GFR]<60 mL/min/1.73 m2) to be
5.2% [8]. The accepted international definition of CKD is abnormalities of kidney structure or
function present for3 months, with implications for health [9]. This definition essentially
comprises either low excretory kidney function and/or the presence of kidney damage. GFR is
recognised ‘as the best overall measure of kidney function, and is frequently used in the diagno-
sis, staging, and management of CKD’ [10]. In the absence of other evidence of kidney damage,
CKD is defined by a GFR threshold of<60 ml/min/1.73m2 [11]. Excretory kidney function is
commonly assessed using estimates of the GFR (eGFR) derived from serum creatinine mea-
surements and using equations that take account of age, gender, and ethnicity. Detection of
albuminuria (increased urinary losses of albumin, including lower amounts historically
referred to as microalbuminuria) is also used to identify kidney disease as it indicates the pres-
ence of kidney damage irrespective of whether there is also low excretory kidney function [12].
Urinary reagent strip (‘dipstick’) testing is commonly used to screen patients for albuminuria.
In order to lessen or remove the impact of kidney failure and lower the risk of cardiovascular
disease (CVD) events, patients from both general and high-risk populations such as those with
diabetes and hypertension may be screened using eGFR and albuminuria testing with the goal
of identifying high risk patients eligible for management to slow the progression of CKD and
lower the risk of CVD events [13].
In CKD screening and monitoring are the most common approaches to medical testing.
Screening targets patients that are apparently healthy and seeks to identify early disease or
emerging risk factors. Monitoring involves using a test repeatedly at various points in time, tar-
geting patients that already have disease e.g. patients with CKD<60 ml/min/1.73m2, hyperten-
sion, diabetes, etc., to identify any changes in their disease status that would warrant new
treatment or a change in treatment regime.
However screening for CKD in the general population may have a negative impact on
patients. Although previous studies have suggested that positive CKD tests do not cause psy-
chological harm to patients [14–16], there is still the burden on the patient of having to receive
further confirmatory testing, referral to secondary care, and potentially unnecessary treatment
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[17]. From the perspective of the health care provider there are the costs incurred due to addi-
tional patient visits and extra testing, all of which could be spent on other services [18]. Indeed,
one of the key issues with CKD is that because the progression of disease is relatively low com-
pared to the variability of the measure used to monitor progression, namely change in GFR or
increase in albuminuria, there are likely to be many false positive test results [12].
During the implementation of a testing and diagnostic pathway, delays can occur which
prevent patients accessing the optimum treatment pathway for their condition. For example, if
testing is delayed then patients that have asymptomatic disease will not get access to the treat-
ment they need, which may lead to unnecessary progression of disease. Then once patients
have been tested, delays may occur while waiting for a definitive test result. Furthermore, once
the need for treatment has been established, there may be delays accessing this treatment. All
of these delays may have an impact on the quality of life of patients. In all cases there is the pos-
sibility of the unnecessary progression of disease, while waiting for confirmatory testing and
then treatment may lead to unnecessary anxiety. Unnecessary delays may also occur as a result
of inefficient health care systems or may be the result of inaccurate testing. For example, a false
negative test may give patients false assurance about their health status but result in unneces-
sary disease progression, potentially leading to increased costs for the health care provider as a
result of having to treat more advanced disease later, which is typically more expensive. Even
in people with non-progressive CKD the situation is further complicated by the increased like-
lihood of significant associated complications such as cardiovascular disease events, acute kid-
ney injury, infections, hospitalisations and all cause mortality [19].
An economic evaluation is a comparative study that examines the difference between costs
and benefits between two or more options and is used in the estimation of cost effectiveness.
There are three main types of economic evaluation: (1) the cost-effectiveness analysis (CEA)
which uses an outcome measure in natural units, e.g. cost per case detected, or cost per patient
treated; (2) the cost benefit analysis (CBA) which uses an outcome measure in monetary units;
and (3) the cost-utility analysis (CUA) which uses the quality adjusted life year (QALY) as the
outcome measure. One QALY is defined as one year of life lived in perfect health, and is often
the preferred outcome measure in economic evaluations due to its comparability across disease
areas. An economic evaluation is conducted from a specific perspective that indicates which
costs should be included in the analysis. A health provider perspective means that only the
costs incurred by the health care provider will be considered in the analysis, while a societal
perspective expands on this perspective to include wider societal costs including the costs
incurred by patients, such as travel time and loss of income [20].
Trial based economic evaluations just take cost and outcome data directly from a trial and
use these to inform the cost-effectiveness of an intervention over the time horizon of the trial.
This approach benefits from being able to take advantage of well designed studies to ensure
that the conclusions drawn from the analysis are unbiased. However it is limited to drawing
conclusions from only one source of data which may not be representative of the wider popula-
tion from which it is drawn, and is limited to conducting analysis over the time horizon of the
trial, which may not be appropriate for chronic diseases. In contrast, model-based economic
evaluations allow the synthesis of data from different sources and allow analysis to continue
beyond the end of a trial. This latter approach is more relevant to patients and health care pro-
viders who have to consider the impact of these diseases over many years [20]. Ideally the time
horizon adopted for a chronic disease should be life-time to ensure that all the patient costs
and outcomes are contained within the analysis. However the model-based approach does rely
on assumptions in order to produce a working model and any analysis will only be as good as
the validity of these assumptions. For example, assumptions are required to formulate the
structure of the model, the costs that are applied beyond the end of the trial, and patient
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outcomes in the long term. Thus checking the appropriateness of the modelling approach is of
importance to ensure that the conclusions drawn from a model-based analysis are valid.
The objective of this systematic review was to examine the published literature that has
reported model based economic evaluations that focus on testing and screening for CKD. Its
purpose is not to draw conclusions about the cost-effectiveness of different interventions;
rather it is to examine how economic models are implemented in this setting. Of particular
interest was to gain a greater understanding of how the impact of test accuracy has been incor-
porated into these analyses, how delays along the testing and diagnostic pathway have been
modelled, and whether the impacts of the testing and diagnostic pathway on patients in terms
of its effect on quality of life (e.g. anxiety following a positive test) and the costs incurred by
patients have been properly considered.
Methods
Inclusion Criteria
This study sought to identify model-based economic evaluations that focused on testing for,
and diagnosis of, CKD. To be included in this review, studies had to meet the following criteria.
They had to focus on albuminuria-based and/or eGFR based testing for CKD and be an eco-
nomic evaluation, namely CEA, CUA, or CBA that reported an incremental cost-effectiveness
ratio (ICER), which is the ratio of the difference between costs and outcomes between the inter-
ventions considered in the analysis. Only studies that focused on general, hypertensive and dia-
betic populations were incorporated, and for studies where the patients were already diagnosed
with CKD, only patients with eGFR15 mL/min/1.73m2 were considered, with those that
focused on patients with kidney failure (eGFR<15 mL/min/1.73m2) being excluded from this
review. Studies also had to be model-based with those that used costs and outcomes measured
from a trial being excluded from this analysis.
Search Strategy
Articles were identified through searches of electronic databases and hand searching of the bib-
liographies of the included studies. Studies were limited to those that focused on humans and
published in English language. The following databases were searched: Medline (In-Process &
Other Non-Indexed Citations and Ovid MEDLINE(R), 1948 to Present), Embase (Embase
1974 to Present) and PsycINFO (1967 to present) accessed via Ovid SP; CINAHL (from 1981
to present) accessed via EBSCO, The NHS Economic Evaluation Database and the HTA data-
base both accessed via the Cochrane Library (Wiley). The search strategy was customized for
each database and used a combination of key terms such as “chronic kidney disease”, “cost-
effectiveness”, “economic evaluation”, “diagnosis”, “testing”, “proteinuria”, “hypertension”,
“diabetes”, “GFR”, “eGFR”, and “microalbuminuria”. Medical Subject Headings (MeSH) terms
were applied to each search strategy where appropriate (see S1 Appendix).
Selection of papers for review
In order to judge the final suitability of studies for inclusion in this review, each study was
grouped independently by two of the investigators (A.S. and K.B.) by examining its title and
abstract where available, based on the initial criteria described in Table 1. Consensus resolved
any differences. The full text was obtained from articles in Groups A-D, and examined to judge
their suitability to be included in the review.
For each paper included in this systematic review, data extraction was conducted in order to
answer the following research questions (see S2 Appendix):
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• Test accuracy—was the accuracy of each test defined, justified and incorporated in the analy-
sis? How did test accuracy impact on patient outcomes? Were the parameters that define the
test accuracy subjected to any sensitivity analysis?
• Modelling approach—what type of model was used (e.g. Markov, decision tree)? How was
progression of the chronic nature of CKD described in the analysis?
• Patient outcomes—was the time delay as a result of patients not being placed on the opti-
mum treatment (or management) pathway reflected in the patient outcomes? Did the analy-
sis include the impact on patient outcomes as a result of changing the timing of testing,
decision-making and treatment?
• Economic outcomes—were the costs incurred by the patients (societal costs) along the testing
pathway incorporated into the analysis
The methodological quality of each paper was assessed through the use of a ten-item check-
list [21] (see S3 Appendix). A score was assigned to each paper based on how well it met the
criteria; scores of 1.00, 0.50 and 0 were assigned to “yes”, “cannot tell” and “no”, respectively.
Thus each paper scored from 0 (bad quality) to 10 (good quality) [22]. The aim of this system-
atic review was to examine the methods used in describing testing and diagnostic pathways in
economic evaluations in this field and not to comment regarding the results and conclusions
drawn from these studies. Consequently, no studies were excluded from this review due to
issues regarding quality.
Results
Study Selection
The searches were conducted on 17th February 2015; a flow diagram describing the outcome of
these searches is shown in Fig 1. The initial search strategy of the databases identified 2,671
studies of which 908 were duplicate studies and 1,689 were excluded because they contained no
material of relevance to this study. Hence, 74 studies were selected for full-text review. Overall,
21 studies met the criteria for inclusion in this systematic review (Table 2), including some
studies that were originally misclassified as being in Groups B-D based on their title and
abstract.
Table 1. Initial categorization of studies.
Group Criteria Action Notes
A Reported a model-based economic evaluation that incorporates one or
more albuminuria- and/or eGFR-based testing strategies targeting the
hypertensive, diabetic, or general population
Retrieved full
text
B Reported an economic evaluation that incorporates one or more
albuminuria- and/or eGFR-based testing strategies targeting the
hypertensive, diabetic, or general population
Retrieved full
text
Unsure if model-based
C Discussed costs and impacts of one or more testing strategies targeting
the hypertensive, diabetic, or general population
Retrieved full
text
Unsure if model-based economic evaluation or
unsure if focused on albuminuria- or eGFR-based
testing
D Discussed the costs and impact of one or more testing strategies Retrieved full
text
Generally unsure about contents
E Not relevant Exclude E.g. not focused on appropriate testing, or
inappropriate patient group, not an economic
evaluation
doi:10.1371/journal.pone.0140063.t001
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Characteristics of Selected Studies
Of the studies in this review, 19 considered proteinuria, of which 6 were focused on reagent
strip (‘dipstick’) proteinuria testing and 13 on albuminuria. Three studies evaluated eGFR test-
ing (one study incorporating both proteinuria and eGFR). One further study described the
parameterisation of a model of CKD without considering an intervention [23], but this was
considered in this review since this model was subsequently applied in a number of other stud-
ies [24–26]. Eight studies originated from the US, three studies were from Canada and the
Netherlands, and one each from Australia, France, Germany, Japan, UK, Switzerland, and
Thailand.
The majority of studies focused on adults drawn from the general population [23–31], with
one study considering schoolchildren [32]. Ten studies focused on monitoring patients with
diabetes [12,33–41] and two studies considered monitoring patients with diabetes and
Fig 1. Identification of studies for final review.
doi:10.1371/journal.pone.0140063.g001
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Table 2. Characteristics of included studies (UAE- urine albumin excretion, GFR-glomerular filtration rate, UPCR-urine protein to creatinine ratio,
UACR-urine albumin to creatinine ratio, LYG-life years gained, QALY-quality adjusted life year, CKD-chronic kidney disease).
Study Study
Population
Method Type of
Testing
Timing Outcome Modelling
Approach
Perspective Test
accuracy
considered
Adarkwah
et al (2010)
Germany
Newly diagnosed
2 type diabetes
Aged 50
albuminuria (UAE 30–300
mg/d); gross albuminuria
(UAE >300 mg/d)
Monitoring Annual LYG /
QALY
Markov Health care
provider
Yes
Adarkwah
et al (2011)
Netherlands
Newly diagnosed
2 type diabetes
Aged 50
albuminuria (UAE 30–300
mg/d); gross albuminuria
(UAE >300 mg/d)
Monitoring Annual LYG /
QALY
Markov Health care
provider
Yes
Boersma et al
(2010)
Netherlands
General
Population Aged
28–75
Albuminuria (UAE 30–300
mg/d)
Screening One-off LYG Markov Health care
provider
Yes
Boulware
et al (2003)
US
General
Population Aged
50
Proteinuria (reagent strip) Screening Annual QALY Markov Societal Yes
Den Hartog
et al (2009)
US
General
Population
(Hypothetical)
Aged 60
eGFR (<60 ml/min/1.73m2);
serum creatinine 1.06–1.36
(mg/dl)
Screening Annual QALY Markov Health care
provider
Yes
Farmer et al
(2014) UK
Type 1 and Type
2 diabetes
patients
UACR (>2.5mg/mmol for
men and >3.5mg/mmol for
women)
Monitoring Annual QALY Individual
based
simulation
model
Health care
provider
Yes
Golan et al
(1999) US
Newly diagnosed
diabetes aged 50
albuminuria (UAE 30–300
mg/d); gross proteinuria
(UAE >300 mg/d)
Monitoring Annual LYG /
QALY
Markov Societal No
Hoerger et al
(2010) a & b;
US
General
Population (US)
aged 50–90
Albuminuria (UAE 30–299
mg/d)
Monitoring 1-, 2-, 5-,
10-years
QALY Micro-
simulation
Markov
Health care
provider
Yes
Hoerger et al
(2012) US
African / non-
African
Americans Aged
50+
Albuminuria (UAE 30–299
mg/d)
Monitoring 1-, 2-, 5-,
10-years
QALY Micro-
simulation
Markov
Health care
provider
Yes
Howard et al
(2010)
Australia
Hypertensive /
diabetic cohort
(Simulated) Aged
50+
Proteinuria (reagent strip
followed by spot UACR >20
mg/mg conﬁrmatory test)
Monitoring Annual QALY Markov Health care
provider
Yes
Kessler et al
(2012)
Switzerland
General
Population Aged
50+
Albuminuria (UACR 30–299
mg/g)
Screening 1-, 2-, 5-,
10-years
QALY Micro-
simulation
Markov
Health care
provider
Yes
Kiberd et al
(1995)
Canada
Patients with
insulin dependent
diabetes mellitus
for 5 years
Albuminuria (UAE >20 μg/
min) or hypertension or
macroproteinuria, or both
(dipstick >0.3 g/l or positive
Albustix conﬁrmed with
>300 mg/d or UAE >200 μg/
min proteinuria)
Monitoring Annual QALY Markov Third party
and
government
Yes
Kiberd et al
(1998)
Canada
Patients with
insulin dependent
diabetes mellitus
for 5 years
albuminuria (UAE >20 μg/
min or UACR 30 mg
albumin/g creatinine);
macroproteinuria (dipstick
>0.3 g/l or positive Albustix
conﬁrmed with >300 mg/day
or >200 μg/min proteinuria)
Monitoring Annual LYG /
QALY
Markov Third party
and
government
Yes
(Continued)
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hypertension [42,43]. In all included studies, testing was either administered in primary care or
had no stated setting.
The time horizons adopted in these studies were based either on the final age of the patient
population or on a specific period of time. Six studies conducted model analysis until the
patient population had reached 75 years old or more [24–26,28,3043]. Three Studies adopted a
lifetime time horizon until all the patients had died [31,35,41]. Four Studies adopted a time
horizon of 50 years or more [33,34,38,39], Five studies adopted 25–30 years [12,36,37,40,42],
and Two studies implemented time horizons of less than 20 years [27,29]. Only one study did
not incorporate a time horizon. This study adopted a decision tree approach and considered
the cost per case of CKD detected for urine dipsticks targeting school-aged children [32].
Modelling Issues and Quality
The quality assessment scores applied to each study in this review ranged from 6.5 to 10 (S4
Appendix). The majority of studies had a score of 9 or more (n = 17), but only 2 studies had
perfect scores. The mean quality score was 8.7 across all studies and the standard deviation was
0.98. All but three studies [29,36,43] lost one point for not discussing all the issues relevant to
users, which in this case meant that the studies did not discuss the impact of testing from the
patient perspective (e.g. costs incurred, anxiety, etc.).
Eight studies in this review examined the cross-validity of the model results by comparing
them to results obtained from other similar studies [27,30,33,34,36,39,42,43]. Five studies
Table 2. (Continued)
Study Study
Population
Method Type of
Testing
Timing Outcome Modelling
Approach
Perspective Test
accuracy
considered
Kiberd et al
(1999) US
Male (Pima
Indians) with
diabetes at
diagnosis
albuminuria (UACR >3 mg
albumin per 1 mmol of
creatinine or UACR >30 mg
per 1g of creatinine)
Monitoring Annual LYG Markov Third party
and
government
No
Kondo et al
(2012) Japan
General
Population Aged
40–74
Proteinuria (reagent strip)
eGFR (<50ml/min/1.73m2)
Screening One-off QALY Markov Societal No
Le Floch et al
(1993)
France
Fictitious cohort
of 10,000
diabetes patients
Albuminuria (UAE >20 μg/
min)
Monitoring Annual QALY Markov Health care
provider
Yes
Manns et al
(2010)
Canada
General
Population
eGFR (<60 ml/min/1.73 m2) Screening One-off QALY Markov Health care
provider
No
Palmer et al
(2008) US
Type 2 diabetes
and hypertension
Albuminuria (UAE 20–
199 μg/min)
Monitoring Annual QALY Markov US third-party
health
insurance
payer
Yes
Sekhar et al
(2010) US
School children
aged 8–15
Proteinuria (reagent strip) Screening One-off Case of
CKD
diagnosed
Decision
Tree
Health care
provider
Yes
Siegel et al
(1992) US
Newly diagnosed
with diabetes
Aged 15
Proteinuria (>300 μg/min) Monitoring Annual LYG Markov Health care
provider
No
Srisubat et al
(2014)
Thailand
45 year old
patients with
diabetes with
normotension
Proteinuira (reagent strip) Monitoring Annual QALY Markov Societal Yes
doi:10.1371/journal.pone.0140063.t002
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examined both the internal validity of the model and its cross-validity [12,24–26,31]. Eight
studies did not examine the validity of the models or their results [28,29,32,35,37,38,40,41].
How was test accuracy considered in the analysis?
Four studies did not consider the issue of test accuracy at all [30,31,40,41], with the remainder
considering the issue to some extent. Only one study which examined serum creatinine versus
eGFR explicitly modelled all the different permutations of test status following a test i.e. true
positive, true negative, false positive, and false negative [29]. In this case, for patients with a
false positive test result, these were assumed to incur the one-time costs of diagnostic workup
before being returned to the true negative state after one cycle which in this model was one-
year. In this study eGFR reporting was found to be cost-effective compared to serum creatinine.
At baseline, the authors assumed that a false positive test result would not have any impact on
patient health. However, when this assumption was relaxed during sensitivity analysis with the
assumption that a false positive test might impact on QoL for one year, it reversed the conclu-
sions drawn from the model with serum creatinine testing becoming more cost-effective com-
pared to eGFR. Patients in the false negative state were assumed to remain unaware of their
disease status, until the next cycle, and the next round of screening one year later, leading to
unnecessary disease progression and the possibility of reaching kidney failure before being
identified as requiring treatment.
In the other studies where test inaccuracy was considered, eight studies (one testing for
eGFR [29]) incorporated its impact on the analysis by including the unnecessary additional
costs incurred due to confirmatory tests amongst patients that tested false positive [12,24,26–
29,42,43]. However in all cases the possibility of the confirmatory tests also being false positive
was not examined and the impacts on patients of the initial positive test (e.g. increased anxiety)
were also not incorporated. Where the possibility of a false negative test was incorporated into
the analysis, this was implemented by assuming that the patient had to wait one time cycle
(one year in all cases) before being offered another test, with the patient thereby experiencing
unnecessary disease progression for at least one time cycle [24,28,29,36,37,42].
Finally, the evidence used to inform sensitivity and specificity values was frequently taken
from single studies [24,26,32,36,37,42,43], rather than using more robust evidence from meta
analyses or a systematic review. Interestingly in the studies by Adarkwah et al [33,38] adopting
a specificity of 100% in the base-case analysis was regarded as a conservative approach as ‘treat-
ing false positives leads to cost savings’. However confirmatory testing or any negative impacts
on the patient of a positive test were not incorporated into the analysis.
What approach was used in the modelling of disease progression?
The majority of studies used a Markov model approach to model disease progression (see
Table 2). Four studies applied a micro-simulation approach to a Markov model structure [23–
26]. This means that the model followed patients individually as they passed through different
states of the Markov model rather than monitoring populations of patients. One study utilized
an individual based model structure in which the timing of a cardiovascular event was esti-
mated in order to estimate lifetime outcomes and the quality-adjusted life expectancy associ-
ated with different screening strategies [12]. Only one study did not model disease progression
and instead used a decision tree approach to establish the cost-effectiveness of identifying cases
of CKD amongst school children [32].
Amongst the studies that described the progression of CKD this was conducted through the
use of progressive albuminuria or GFR states. Only 3 studies explicitly allowed for the possibil-
ity of the reversibility in CKD severity [12,27,36], In one further study there was no progression
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between stages of CKD, instead the probabilities of progression to ESRD were based on the
renal function stratum of the initial population at time zero [30]. In another, CKD was repre-
sented as a single health state [31].
Were the impacts of any delays on the testing and treatment pathway
considered?
Since the majority of the studies incorporated in this review focused on screening, the most com-
mon type of delay considered was in getting disease positive patients tested for the first time. The
screening studies in this review all considered annual screening [12,24–26,28,29,33,36–43]. A
number of studies then extended this screening interval in sensitivity analysis up to 10 years
[12,26,28], thereby implying that a patient that becomes eligible may have to wait up to 10 years
before diagnosis and treatment is offered. Interestingly no study considered the possibility of a
screening interval of less than 1 year. It is noted that screening interventions tend to become
more cost-effective for longer screening intervals as under these circumstances it is likely that
more true positive individuals that are eligible for treatment will be identified during each screen-
ing event (e.g. Hoerger et al (2010), Hoerger et al (2012) and Kessler et al (2012) [24–26]. More-
over there were no studies that considered the possibility of symptomatic patients seeking
diagnosis and treatment outside of the defined screening intervals.
No studies considered the possibility of a delay in receiving results following testing. While
it is acknowledged that for the modern health care systems considered in this review, these
delays will be minimal, delays in the communication of abnormal test results to patients can
still occur. In addition, receiving immediate treatment following a confirmed positive test
seems to be an implicit assumption made in all of the studies where testing and treatment was
considered.
Were costs incurred by patients (societal costs) along the testing
pathway considered?
Four studies reported adopting a societal perspective [28,30,36,41], with the remainder using
only a health-care provider perspective. In the case of the study by Kondo et al (2012) [30],
only the costs incurred as a result of the costs of the tests, a detailed patient examination, and
then various treatments are incorporated in the analysis, while in the study by Boulware et al
(2003) [28] direct costs of medical care were considered as well as the indirect costs of loss of
income for people disabled as a result of kidney failure. In the case of Srisubat et al (2014) [36],
this study considered the costs for patients as a result of albuminuria progression due to the
food, travel, and opportunity costs incurred as a result of travelling to receive testing. Golan
et al (1999) [41] reported using a societal perspective, but did not report costs in sufficient
detail to gain an understanding of how costs incurred by patients might be incorporated into
the analysis. Aside from the study by Srisubat et al (2014) [36] there were no studies that con-
sidered the costs incurred by patients as a result of travel costs and loss of income as a result of
having to attend for testing (and re-testing). Although this was mitigated as in some cases it
was stated that testing could be conducted during a regular primary care appointment [28,35].
Discussion
This systematic review has focused on the approaches used in model-based economic evaluations
of testing and diagnosis for CKD. Twenty-one studies were identified and data was extracted
from these to gain insights into how test accuracy, delays along the testing and treatment path-
way, and the costs incurred by patients were incorporated in the analysis. Test accuracy was
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considered in 17 of the studies in this review, although its full implications on model results were
not always examined. Typically only the possibility of false positive tests was incorporated in the
analysis with patients either assumed to undertake further testing to confirm the original test
result, or else receive unnecessary management and treatment. In the case of repeated testing,
only the costs of the repeat tests incurred by the health care provider were incorporated into the
analysis. This approach meant that the impact on the patient of receiving a false positive test
result was overlooked, and as a result the costs incurred by patients in terms of travel costs and
loss of earnings due to having to return for further testing were usually not incorporated in the
analysis, and neither was the impact of the anxiety associated (i.e. potential reduction in quality
of life) with having received a positive test. Moreover the failure to incorporate confirmatory test-
ing for initially positive test results in many of these studies is also a concern, since the variability
of the test results for patients in this setting (particularly the elderly) may mean that in the
absence of confirmatory testing, patients could be given inappropriate treatment.
False positive tests potentially have a large impact on results drawn from models where the
prevalence of a disease is very low [44]. Under these circumstances it is much more likely that a
positive test will be false and as such false positive results may have a large impact on the con-
clusions drawn from a model. For CKD, this is likely to be the case only when screening is tar-
geting younger age groups of the general population where the prevalence of CKD is lower.
Only one study incorporated the impact of the anxiety associated with a false positive test, and
interestingly found that changing this value across reasonable bounds led to changes in the
conclusions drawn from the study, with serum creatinine being preferred to eGFR when larger
quality of life adjustments for a false positive CKD diagnosis were applied in the model. In the
case of false negative test results these were frequently not considered in these analyses, but
when they were, it was assumed that patients with disease would progress as normal until the
next opportunity to get tested. False negative tests become important when the prevalence of a
disease is very high, and then it becomes more likely that a negative test may be false [44].
The main delays on testing and diagnostic pathways that are modelled in this setting are the
delays in disease positive individuals getting tested. These delays are modelled by describing
the interval between screening events, and in this setting these intervals are always assumed as
being one year or longer. Delays due to receiving testing are obviously important in this setting
as these can lead to patients experiencing unnecessary progression of their disease; by contra-
distinction it is likely to be cost-effective to extend the screening interval when targeting the
general population as most of the population will not experience disease progression. Delays
due to symptomatic individuals seeking or failing to seek diagnosis were never considered.
This would obviously be more relevant for studies that focused on high-risk individuals such as
people with diabetes or those suffering hypertension, and might have an impact on the conclu-
sions drawn from the models. Delays in passing on test results to patients, and delays in
patients receiving treatment following a positive test result were never considered. The studies
in this review were all conducted in developed settings and so delays like this may be less com-
mon, but nevertheless these are issues that might be considered more widely.
Four studies considered a societal perspective; with only one of these studies incorporating
the costs incurred by patients as a result of having to attend for testing such as those due to
travel costs and the potential loss of income. In some settings e.g. UK, the advice given when
conducting economic evaluations is that a health-care perspective should be adopted, meaning
that the costs incurred by patients would be outside the scope of the analysis. In addition, some
of the studies in this review mentioned that the testing could be conducted alongside a prear-
ranged primary care appointment which would minimize the costs incurred by the patients.
Nevertheless patient incurred costs may still be significant, particularly in groups with lower
disease prevalence where there are more likely to be false positive tests. It could therefore be
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argued that only using a health care provider perspective in this and many other settings that
consider medical testing may be inappropriate for incorporating some of the issues that are
important to patients.
In the majority of studies, no possibility of the reversibility of CKD severity was incorporated
into the models. However a small proportion of patients (e.g. people with diabetes) with
eGFR>60mL/min/1.73m2 with stage 1 or 2 CKD do either spontaneously revert to normalbu-
minuria or do so under the influence of blood pressure (BP) control, specifically RAAS (Renin-
angiotensin-aldosterone system) blockade (with ACE-I or ARB). Similarly, in a small propor-
tion of patients (10–15%) with more advanced CKD with severe hypertension of significant
albuminuria, stabilisation of BP control, and implementation of RAAS blockage, can lead to
moderate improvements in renal function. These improvements need not be sustained, and
experience suggests that the majority of patients then decline again, but perhaps at a slower rate.
From an economic perspective, the implications of ignoring these issues are that additional
treatment may be assumed for patients that do not need it, leading to extra costs being incorpo-
rated into the analysis. Moreover, additional unrealistic disease progression may lead models
to predict more deaths and cases of ESRD than is realistic. While it is acknowledged that it is
often difficult to obtain parameter values which describe reverse progression, this should be
attempted where possible in order to design more realistic models.
This review incorporated extensive searches of a multiple electronic databases which has
increased the likelihood of identifying all the relevant papers in this topic area. This review
could have been expanded to incorporate non-English studies; while the grey literature, which
is academic literature that is not formally published, was also not considered. With the focus
on this study being on the methods used in model based economic evaluations, a further limi-
tation of this study is that the inclusion criteria meant that the studies included in this review
sought to answer different research questions, meaning that an overall conclusion regarding
the results obtained from these studies could not be drawn. To our knowledge this is the first
study that has focused on the methods used in economic evaluations of testing and diagnosis
in CKD to describe the testing and diagnostic pathway and the factors that are important to
patients. Previous reviews in this area have focused on the results obtained from the studies
[45] rather than issues related to the testing pathway that may have a significant impact on
patients.
This systematic review has shown that many of the issues that are important to patients
when undertaking economic evaluations in diagnosis and monitoring for CKD are often not
considered. The impact on patients of a false positive test as a result of the additional costs
incurred by patients through receiving further confirmatory tests is frequently overlooked.
Moreover at least one study in this review has shown that the inclusion of the impact on quality
of life for patients that receive false positive tests has the power to change conclusions drawn
from the analysis. Of course it cannot be said that this will be the case in all groups of people
with CKD, but the fact that it has not been considered in many previous studies is of concern.
Linked to the issue of false positive tests is the wider issue of test accuracy. It is worrying that
studies have been conducted in this area in which test accuracy has not been considered in the
evaluations. Aside from the issues related to false positive tests described above, a false negative
test result means that a cost has been incurred by the health care provider (and patient), but
has provided no patient benefit.
Future economic evaluations in this area should incorporate test accuracy, and where possi-
ble a societal perspective should be adopted. Even if the advice is to use a health care perspective,
at the very least a societal perspective should be considered in sensitivity analysis, as it would be
important to determine whether this has a significant impact on the conclusions drawn from a
model. To ensure these factors are adequately incorporated into an analysis, Fig 2 provides
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some suggested questions that could be asked when conducting an economic evaluation that
incorporates patient testing. While these questions are not definitive, or may not be appropriate
for all settings, considering them will ensure that many of the issues that impact on patients are
considered in the analysis. At the present time in which patients are becoming ever more
involved in setting the research agenda and guiding approaches to research, a societal perspec-
tive will become even more important in helping decision makers and patients make informed
choices about the use of screening tests.
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